Dr. Weitzel Discusses the Impact of Gene Mutations on Treatment
Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.
Weitzel believes risk-appropriate management is important. A decade of evidence shows that removing the ovaries of young BRCA carriers almost eliminates the risk of ovarian cancer, as well as breast cancer, adds Weitzel.
There are many challenges that Weitzel and his colleagues face as they try to integrate new genes, and for every gene, there is a chance of finding a variation that is less understood.
Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
